"According to the Association for Accessible Medicines (AAM), last year, generic and biosimilar drugs saved patients in the U.S. health care system approximately $467 billion, and their impact is only growing as more biologic patents expire. Still, realizing their full potential requires more than market availability. Plans require a well-defined strategy, supported by clear metrics, smart formulary design, and strong provider engagement, to convert potential into measurable ROI and improved health outcomes."  MORE >>